MetaCap

Generate Biomedicines (GENB) vs MannKind (MNKD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

MannKind is the larger company by market cap ($1.24 billion vs $1.23 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GENB-24.58%MNKD+17.38%
+66%+15%-35%
Feb 27, 20261 yearNov 20, 2026
GENB-24.58%MNKD+17.38%
+41%+4%-34%
Feb 23, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GENB versus MNKD key metrics
MetricGENBMNKD
Share price$9.54$3.85
Market cap$1.23B$1.24B
1-day change-8.00%-2.53%
YTD return—-32.10%
1-year return—-23.46%
5-year return—-16.85%
Forward P/E—24.44
EPS (TTM)$-2.49$-0.24
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$348.97M
Revenue growth (YoY)—+22.23%
Net income (latest FY)—$5.86M
Gross margin—92.32%
Operating margin—11.12%
Net margin—1.68%
52-week high$22.67$6.51
52-week low$9.40$2.23
Distance from 52-week high-57.92%-40.86%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+183.02%+116.36%
Average volume1.24M3.96M
Shares outstanding129.10M321.64M
Employees312591
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Generate Biomedicines

GENB stock →

Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development.

Health Care · Biotechnology: Pharmaceutical Preparations · 312 employees

About MannKind

MNKD stock →

MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 591 employees

GENB vs MNKD FAQ

Which is bigger, Generate Biomedicines or MannKind?

MannKind (MNKD) is larger, with a market capitalization of $1.24B compared with $1.23B for Generate Biomedicines (GENB).

Are Generate Biomedicines and MannKind in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons